This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: stub-manual Compound SKIP-PERMANENT HIGH

Ibogaine

Extended Research
High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.

Extended Research

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

Editor's verdict SKIP-PERMANENT HIGH

The most cardiotoxic psychedelic in clinical use. ~1 in 300-400 ibogaine sessions in field clinics ends in death, dominantly via QTc prolongation → torsades → sudden cardiac death. Pre-screening (EKG, electrolytes, no CYP2D6-inducing meds, no other QT-prolonging drugs) reduces but does not eliminate the risk. The legitimate clinical case is opioid use disorder with full medical monitoring — there is real published signal there (Mash 2018, Brown 2018, Davis 2017). For a 20yo with no OUD indication, this is gambling permanent cardiac harm against a recreational psychedelic experience. SKIP-PERMANENT means: not used in this archetype. Even the experimental 18-MC (designed to retain anti-addictive effect without hERG block) is still in early human trials and not available. Flips to OPTIONAL only inside a licensed-clinic + cardiology-cleared + OUD-indication context.

Research pass: stub-manual
Sourcing deep dive

Schedule I in US; foreign clinics (Mexico, Costa Rica, Brazil) are the legal route. Quality of underground supply varies; potency varies enormously between Tabernanthe iboga root bark batches. 18-MC (non-cardiotoxic analog) in early clinical development at MindMed and others.

Verdict change log
  • 2026-06-05 — Initial verdict SKIP-PERMANENT. Cardiac risk too high outside OUD-indication clinical context. (stub)
Open questions / gaps Open
  • Whether 18-MC clears Phase 2 with the anti-addictive effect preserved without the cardiac signal.
  • Whether magnesium-protected clinical protocols (Cherian 2024) become the standard and reduce field fatality rate.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…